This research investigates how rising global temperatures threaten tropical insects by examining their thermal tolerance across elevational gradients in Africa and South America. By analyzing approximately 2,300 species, the authors demonstrate that insects in warm lowlands possess minimal physiological flexibility and are already living near their maximum heat limits. The study highlights a significant correlation between an insect's evolutionary lineage and its heat resistance, which is fundamentally tied to the stability of its proteins. Projections suggest that future climate scenarios could push temperatures beyond these biological thresholds, potentially causing widespread heat-induced mortality in the world’s most biodiverse regions. Ultimately, the findings emphasize that intact rainforests and habitat connectivity are vital to providing the thermal refugia necessary for insect survival.

References:

• Holzmann K L, Schmitzer T, Abels A, et al. Limited thermal tolerance in tropical insects and its genomic signature[J]. Nature, 2026: 1-7.

The paper introduces Evo 2, a cutting-edge biological foundation model designed to interpret and engineer life's genomic complexity across all domains. Trained on a massive 9 trillion base pair dataset called OpenGenome2, the model utilizes a sophisticated StripedHyena 2 architecture to achieve a high-resolution 1 million token context window. This scale allows Evo 2 to predict the functional consequences of genetic mutations and identify complex structural features, such as exon-intron boundaries and protein elements, without specific fine-tuning. Beyond analysis, the model demonstrates generative capabilities, producing coherent genomic sequences and experimentally valid biological patterns. Ultimately, the developers have released Evo 2 as an open-source tool to accelerate global research in synthetic biology and clinical genomics.

References:

• Brixi G, Durrant M G, Ku J, et al. Genome modelling and design across all domains of life with Evo 2[J]. Nature, 2026: 1-13.

This research article from Nature Cancer investigates the biological mechanisms driving peritoneal metastasis (PM) in colorectal cancer (CRC). By utilizing single-cell RNA sequencing on matched patient samples, the authors constructed a detailed atlas of the tumor microenvironment across primary and metastatic sites. The study identifies that intestinal microbiota dysbiosis triggers inflammation and the recruitment of specific neutrophils, which facilitates the spread of cancer. Furthermore, the findings highlight a mesenchymal transition in both malignant and mesothelial cells that increases the invasiveness of the disease. Ultimately, the research suggests that targeting the microenvironment and mesothelial cell remodeling could lead to new therapeutic strategies for late-stage CRC patients.

References:

• Li Q, Xiao Y, Han L, et al. Microbiome dysbiosis, neutrophil recruitment and mesenchymal transition of mesothelial cells promotes peritoneal metastasis of colorectal cancer[J]. Nature Cancer, 2025, 6(3): 493-510.

This research identifies pinealocyte progenitors as the specific developmental origin of pineoblastoma, a dangerous pediatric brain cancer. By mapping the genetic landscape of human tumors and creating genetically engineered mouse models, scientists discovered that these malignancies arise during a specific window of high cellular growth. The study reveals a Tumor-Associated Photoreceptor Signature (TAPS) that is molecularly shared between pineoblastoma, retinoblastoma, and Group 3 medulloblastoma. This common signature suggests that these anatomically different tumors exploit the same developmental vulnerabilities to sustain their growth. Crucially, the researchers identified certain master regulatory genes as selective dependencies, meaning the cancer cells rely on them to survive. These findings offer a new framework for understanding rare childhood cancers and point toward therapeutic targets that could treat multiple types of brain and eye tumors.

References:

• Gudenas B L, Ahmad S T, Englinger B, et al. A tumor-associated photoreceptor signature unifies distinct central nervous system malignancies[J]. Cancer Cell, 2026.

This research investigates how lung adenocarcinoma (LUAD) cells survive in a dormant state by utilizing a unique biological transition. While the TGFβ protein typically triggers a movement-oriented change in cancer cells, these specific progenitors instead adopt an atypical mesenchymal state characterized by a round shape and a lack of actin stress fibers. By producing a protein called gelsolin, these dormant cells soften their structure to become biomechanically less stiff, allowing them to hide from the immune system's mechanical detection. This structural softening effectively protects the cancer from being destroyed by cytotoxic lymphocytes during long periods of latency. Ultimately, the study reveals that this morphological shift is a critical survival tactic that enables metastatic cells to persist until they are ready to form active tumors.

References:

• Wang Z, Elbanna Y, Godet I, et al. TGFβ induces an atypical EMT to evade immune mechanosurveillance in lung adenocarcinoma dormant metastasis[J]. Nature Cancer, 2026: 1-19.

This research introduces a novel human brainstem organoid model specifically designed to study diffuse midline glioma (DMG), a lethal pediatric cancer. By using targeted growth factors to mimic the pontine region, scientists successfully generated tumors that replicate the complex genetic and structural diversity found in patients. The study demonstrates that a specific glial developmental window is essential for tumor formation, highlighting why these cancers arise in specific brain regions. Researchers utilized this platform to test GD2 CAR T cell therapy, identifying distinct cell populations ranging from highly effective killers to those that become exhausted over time. Additionally, the integration of microglia into the model revealed how these immune cells create an immunosuppressive environment that hinders treatment success. Ultimately, this sophisticated in vitro system provides a vital tool for exploring disease progression and accelerating the development of new immunotherapies.

References:

• Bessler N, Wezenaar A K L, Ariese H C R, et al. De novo H3. 3K27M-altered Diffuse Midline Glioma in human brainstem organoids to dissect GD2 CAR T cell function[J]. Nature cancer, 2026: 1-18.

This research article from Nature Cancer investigates the microbial landscape within glioblastomas and brain metastases. By analyzing 322 tumor samples, scientists discovered that brain metastases possess a higher variety and richness of bacteria compared to primary brain tumors. The study highlights that microbial communities vary significantly based on the specific tumor type and its location within the brain, with posterior regions showing greater diversity. Metabolic pathway analysis suggests these bacteria may play roles in tumor progression and the spread of cancer. Furthermore, the presence of certain bacteria correlates with patient survival rates and may influence how tumors respond to chemotherapy. Researchers used multiple high-tech methods to confirm that these intracellular bacteria are alive and metabolically active.

References:

• Gigi E, Gavert N, Raijman-Nagar L, et al. Characterization of the tumor microbiome of brain metastases and glioblastoma reveals tumor-type-specific and location-specific microbial signatures[J]. Nature Cancer, 2025: 1-16.

This research article introduces a novel antibody-drug conjugate (ADC) designed to treat T cell cancers by targeting the TRBC2 constant region of the T cell receptor. Unlike existing treatments that deplete all T cells and cause severe immunosuppression, this therapy exploits the fact that individual T cell malignancies express only one of two possible alleles, either TRBC1 or TRBC2. By engineering a high-affinity antibody named JX1.1, the researchers successfully targeted cancerous cells while preserving a significant portion of healthy T cells to maintain immune function. Laboratory tests and animal models demonstrated that this ADC is effectively internalized by tumor cells and delivers a potent cytotoxic payload, leading to tumor regression. This selective approach offers a promising, off-the-shelf therapeutic option for patients with aggressive T cell leukemias and lymphomas.

References:

• Ge J, Urban J, DiNapoli S R, et al. TRBC2-targeting antibody–drug conjugates for the treatment of T cell cancers[J]. Nature Cancer, 2025: 1-14.

This research identifies the chromatin remodeler SMARCA5 as a critical molecular switch that distinguishes cancerous growth from natural tissue repair in the pancreas. While traditional treatments often cause collateral damage by inhibiting factors necessary for both regeneration and disease, scientists found that SMARCA5 specifically maintains the accessibility of DNA regions required for malignancy. In the presence of mutant KRAS, the transcription factor RUNX1 recruits SMARCA5 to "lock in" a neoplastic state, effectively preventing acinar cells from returning to their healthy form after injury. By disrupting the SMARCA5-containing NoRC complex, researchers were able to suppress pancreatic ductal adenocarcinoma (PDAC) without hindering the organ's ability to regenerate. This discovery highlights a spatiotemporal mechanism that can be targeted to treat lethal tumors while preserving essential physiological healing processes.

References:

• Han J, Lu X, Guo M, et al. Spatiotemporal control of SMARCA5 by a MAPK–RUNX1 axis distinguishes mutant KRAS-driven pancreatic malignancy from tissue regeneration[J]. Nature Cancer, 2026, 7(1): 43-59.

This research article utilizes single-cell multiomic analysis to identify a specific subset of cancer cells responsible for treatment failure in T cell acute lymphoblastic leukemia (T-ALL). By mapping over 600,000 cells against a healthy pediatric developmental atlas, scientists discovered a bone marrow progenitor-like (BMP-like) population that is highly resistant to standard chemotherapy and steroids. The presence of these primitive, stem-like cells serves as a powerful prognostic biomarker, accurately predicting poor survival across various leukemia subtypes regardless of traditional risk factors. Genetic analysis further revealed that NOTCH1 mutations help push cancer cells away from this resistant state, while specific fusions drive the aggressive BMP-like phenotype. Ultimately, the study suggests that identifying these high-risk signatures early can guide doctors toward targeted therapies, such as the drug venetoclax, to improve patient outcomes.

References:

• Xu J, Chen C, Sussman J H, et al. A multiomic atlas identifies a treatment-resistant, bone marrow progenitor-like cell population in T cell acute lymphoblastic leukemia[J]. Nature cancer, 2025, 6(1): 102-122.